Neulasta onpro 6 MG/0.6 ML kit 0.6ML
Ended Awarded Last action
- Contract number
- SPE2DR26FJC0N
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,390
Award facts
- Contract value 100% obligated
- $7,389.54 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,389.54 to AmerisourceBergen Drug Corp for the supply of Neulasta Onpro 6 mg/0.6 ml injectable kits, with an ultimate completion date of December 4, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award to the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that supplies an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies to federal military and veteran healthcare systems. The company's selection reflects its established capability to meet federal procurement requirements through open competition and its critical role in supporting the Defense Health Agency and other government healthcare entities with pharmaceutical commodities across multiple therapeutic domains. The Neulasta product supplied under this order is a granulocyte colony-stimulating factor (G-CSF) injection used to support chemotherapy patients and individuals with certain blood disorders within military medical treatment facilities.
Quick answers
Who was awarded contract SPE2DR26FJC0N?
SPE2DR26FJC0N was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FJC0N worth?
The government has obligated $7,390 on SPE2DR26FJC0N.
Is contract SPE2DR26FJC0N an order under another contract?
Yes. SPE2DR26FJC0N is a delivery order under SPE2DR25D1106, an indefinite delivery contract.
Was contract SPE2DR26FJC0N competed?
The extent of competition for SPE2DR26FJC0N was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award